ReviewLipids in health and disease2026
Hypothesis: the rs66698963 insertion-deletion alters the AA/EPA ratio and cardiovascular disease risk.
Review in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) remains the leading cause of mortality worldwide. In addition to established risk factors such as hypertension, dyslipidemia and smoking, genetic variations may modulate individual susceptibility to CVD. The rs66698963 insertion–deletion (indel) polymorphism in the fatty‑acid desaturase (FADS) gene cluster increases fatty‑acid desaturase 1 activity and elevates circulating arachidonic acid (AA) relative to eicosapentaenoic acid (EPA). We hypothesize that carriers of the rs66698963 insertion allele develop a pro‑inflammatory AA‑dominant lipid profile that predisposes them to a greater risk of CVD. This article summarizes existing evidence linking FADS genetics, the AA/EPA ratio and inflammation and proposes observational and intervention studies to test this hypothesis. If confirmed, genotype‑based screening and targeted dietary or pharmacologic interventions could advance precision cardiovascular medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.